M&A Deal Summary

MorphoSys Acquires Constellation Pharmaceuticals

On June 2, 2021, MorphoSys acquired life science company Constellation Pharmaceuticals for 1.7B USD

Acquisition Highlights
  • This is MorphoSys’ 2nd transaction in the Life Science sector.
  • This is MorphoSys’ largest (disclosed) transaction.
  • This is MorphoSys’ 1st transaction in the United States.
  • This is MorphoSys’ 1st transaction in Massachusetts.

M&A Deal Summary
Date 2021-06-02
Target Constellation Pharmaceuticals
Sector Life Science
Buyer(s) MorphoSys
Deal Type Add-on Acquisition
Deal Value 1.7B USD
Advisor(s) Centerview Partners (Financial)
Wachtell, Lipton, Rosen & Katz (Legal)

Target

Constellation Pharmaceuticals

Cambridge, Massachusetts, United States
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with various forms of cancer. Constellation Pharmaceuticals was founded in 2008 and is based in Cambridge, Massachusetts.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

MorphoSys

Planegg, Germany
Category Company
Founded 1992
Sector Life Science
Revenue 278M EUR (2022)
DESCRIPTION

MorphoSys is a global biopharmaceutical company developing innovative medicines in oncology. MorphoSys was formed in 1992 and is based in Planegg, Germany.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 2 of 2
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2021) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-05-07 Lanthio Pharma BV

Groningen, Netherlands

Lanthio Pharma BV is a biopharmaceutical company.

Buy -
Mergr

Product

Company

Legal